Longevinex responds to allegations of scientific fraud by resveratrol researcher

Longevinex responds to allegations of scientific fraud by resveratrol researcher

Independent research confirms that Longevinex resveratrol works superior to plain resveratrol in animal and human studies apart from published studies that have been called into question.

Bill Sardi, managing partner for Longevinex®, a resveratrol-based dietary supplement, says the product his company makes has passed independent scientific scrutiny in human studies conducted both in the USA and overseas and that the animal-lab researcher at the University of Connecticut who has conducted studies involving Longevinex® and whose work has now come under scientific scrutiny, has no business relationship with Longevinex®.
Sardi says, to his knowledge, criticism of Dr. Dipak Das’ work at the University of Connecticut primarily involves irregularities in a test called the western blot analysis which would not alter the findings that Longevinex® has been proven to reduce the area of scar tissue following a heart attack in excised rodent hearts.  
Actual photographs showing the amount of scarring following a heart attack provide incontrovertible evidence that both resveratrol and Longevinex® protect the rodent heart prior to a heart attack by activating protective molecules such as nitric oxide, adenosine and heme oxygenase prior to a heart attack, says Sardi.
“None of the allegations that I have briefly read in newspapers negate the pioneering work of Dr. Das, who first showed that resveratrol can turn a mortal heart attack in animals into a non-mortal event,” says Sardi.  The implications of this discovery are profound given that aspirin has just recently been found to be ineffective in reducing the risk of a mortal heart attack in humans, adds Sardi.
The proposed health benefits involving Longevinex® have been corroborated by independent studies conducted by National Institutes of Health researchers as well as researchers in other centers in the USA and overseas, says Sardi.  Links to these reports are provided here. As early as 2008 resveratrol researchers confirmed that Longevinex® activates 9-fold more genes than plain reseveratrol in rodent hearts.
Sardi says his company has received reports that patients whose coronary arteries were 99% blocked by plaque experienced no chest pain or damage to their heart, evidence that Longevinex® was cardio-protecting the heart.  Sardi says his company has received a report from a cardiologist that an 89-year old man taking Longevinex®, who was judged to be too frail to undergo invasive heart surgery and who had a completely blocked coronary artery, experienced no heart damage and circulation was restored over time on its own.   
Normally the heart releases protective antioxidants following a heart attack, when blood circulation is restored to a coronary artery that provides the heart with oxygenated blood.  But resveratrol, and more so Longevinex®, releases these protective molecules prior to any adverse event, such as a blockage in arteries supplying oxygen to the heart or brain, says Sardi.
“One has to be alerted to the possibility of a witch hunt here,” says Sardi, “since Dr. Das has made landmark contributions to the understanding of resveratrol and how it works.  There are billions of dollars of drug sales that are threatened by resveratrol, which not only protects the heart prior to a heart attack, but thins the blood and prevent clots in coronary arteries, inhibits inflammation, controls cholesterol and dilates (widens) blood vessels to maintain normal blood pressure.  Resveratrol and Longevinex® threaten to replace many problematic heart drugs that have not been demonstrated to reduce mortal heart attacks,” says Sardi.
Sardi says his company underwrites some of the costs of conducting studies by independent researchers by providing product for analysis and by underwriting some of the costs involved in testing and that his company played no role in the design or outcomes of any of the published studies that have now been called into question.  Dr. Das is not a paid consultant to Longevinex® says Sardi.  
The news media chose to implicate Longevinex® in the allegations against Dr. Das without first contacting the company for a response, says Sardi.  “Longevinex should not be considered guilty by association,” says Sardi.
Dr. Das is attending a scientific conference in India and has not been able to respond to the allegations. 

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.